Stargardt disease
Approval decisionStock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| Tinlarebant (LBS-008) | Stargardt disease | PDUFA | Feb 12, 2027 | — |
| Tinlarebant (LBS-008) | Stargardt disease | PDUFA | Feb 12, 2027 | — |
Upcoming milestones
Stargardt disease
Approval decisionCompany profile
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Stargardt disease
Approval decision